WSJ : Eurofin’s Bright Ideas for Espírito Santo

Eurofin’s Bright Ideas for Espírito Santo

Eurofin Holding SA, a small Swiss financial company, for years played a key role providing financial services to the now-collapsed Espírito Santo empire, according to a Page One story in The Wall Street Journal. That role might have been even more expansive if Eurofin executives had their way, according to internal Eurofin emails and documents reviewed by the Journal.

Here are two ideas that Eurofin executives floated that never got off the ground:

Idea #1: Buy Banco Espírito Santo’s bad loans

In 2009, banks were struggling with growing piles of bad loans. Regulators were pressuring lenders to clean up their balance sheets, while continuing to provide credit. So Eurofin had an idea: what if Banco Espírito Santo sold its bad loans to an investment fund set up by Eurofin, which in turn would get a loan from the bank to finance its purchase of those assets? Besides helping the bank, Eurofin’s fund would make money from outside investors.

In a 2009 email to colleagues, Eurofin executive James Edwards outlined the idea: “the critical thing for these sorts of deals to make sense is that the bank cannot invest in the shares or equity of the fund….it can however make a loan to the fund.”

He continued: “Our value added is pretty obvious. We are an arms length manager… We can add additional investment expertese [sic] in the management of these assets that will free up significant bank management time. We provide a potential solution to their balance sheet and also to the income statement as they will be receiving loan interest from the fund.”

Alas, the idea never came to fruition. In an emailed statement to the Wall Street Journal, Eurofin said “this was a commercial proposal to Banco Espírito Santo which never materialized.” Espírito Santo declined to comment. Mr. Edwards didn’t respond to requests for comment.

Idea #2: Sell Eurofin hedge funds to Espirito Santo clients

Also in 2009, Eurofin and Banco Espírito Santo executives met in Lisbon to discuss setting up a Eurofin hedge-fund unit, according to an email among Eurofin executives at the time. The unit “will be the product provider for the Espirito Santo distribution networks,” Mr. Edwards wrote to colleagues recounting his meeting with a top bank executive.

Eurofin said in its statement to the Journal that Mr. Edwards proposed the idea, “but the discussion went no further.”

In 2011, Eurofin ended up buying a small London hedge fund called NAU Capital LLP. The hedge fund’s primary investor was Banco Espírito Santo, and one of its principal employees was João Poppe, the nephew of the bank’s CEO. Mr. Poppe didn’t respond to requests for comment. Nor did Mr. Edwards. Espirito Santo declined to comment.

WSJ : Behind the Collapse of Portugal's Espírito Santo Empire

Behind the Collapse of Portugal's Espírito Santo Empire
Regulators Believe Switzerland's Eurofin Played Key Role in Financing Failed Conglomerate

Over nearly 150 years, Portugal's Espírito Santo clan built a corporate dynasty whose interests ranged from European banks to Miami condos to a diamond mine in Angola. Its current patriarch was nicknamed "Dono Disto Tudo," or "Owner of All This."

Now the empire is in ruins. The family's prized asset and Portugal's second-biggest bank, Banco Espírito Santo SA, BES.LB -40.30% collapsed this month, and Espírito Santo's main holding companies have filed for bankruptcy amid allegations of accounting problems and fraud.

The scandal has rocked Portugal's political and business elites and sent shock waves through Europe's fragile financial markets. Portugal's main stock-market benchmark has tumbled 22% since Espírito Santo's crisis intensified early last month. The fact that regulators didn't spot the company's problems has rekindled fears among investors that trouble might be lurking in other European banks.

At the heart of the affair lies a small Swiss financial company now called Eurofin Holding SA, which was set up 15 years ago largely to handle financial transactions for the Espírito Santo family and its companies.

For years Eurofin was partly owned by an Espírito Santo company. Eurofin played an important role in buttressing Espírito Santo's finances, according to internal Eurofin emails, trading records and other documents reviewed by The Wall Street Journal, as well as former executives and other people familiar with the relationship.

The records indicate that Eurofin moved money between Espírito Santo entities, often in ways that were difficult for outsiders to detect. Some of the moves took place in the heat of the global financial crisis, when southern European banks were struggling to stay afloat.

At times, a Eurofin-managed vehicle was the only buyer of certain Banco Espírito Santo bonds, trading records show. Eurofin helped package large sums of debt from various Espírito Santo companies, which were then sold to the bank's customers. One arrangement attracted attention from a top French bank's compliance department, prompting that bank to stop processing transactions between Eurofin and Espírito Santo, according to a person familiar with the matter.

Portugal's central bank governor, Carlos Costa, now says the shuffling of funds among Espirto Santo companies amounted to fraud. Espírito Santo "developed a fraudulent funding scheme between the companies belonging to the group," Mr. Costa said recently. He added that "these frauds are very difficult to detect before they collapse, in particular when activities are carried out in various jurisdictions."


Family patriarch Ricardo Espírito Santo Salgado, shown in a 2010 photo, resigned as CEO of publicly traded Banco Espírito Santo in July. Associated Press
Portuguese regulators suspect that Eurofin played a central role in the Espírito Santo affair, according to a person familiar with the investigation.

Eurofin, a privately held company based in Lausanne, Switzerland, said in a written statement that it "is fully autonomous and independent" of Banco Espírito Santo and the wider Espírito Santo Group. Eurofin confirmed that it had extensive business dealings with Espírito Santo entities, but said the company "has always acted in full compliance with applicable laws and regulatory requirements." The company said it never distributed any financial products to retail customers.

Alexandre Cadosch, chief executive of Eurofin, said in a brief interview Tuesday: "I firmly believe we are the wrong target."

A spokesman for Espírito Santo International SA, the family's main holding company, which filed for bankruptcy last month, declined to comment.

Family patriarch Ricardo Espírito Santo Salgado resigned as chief executive of publicly traded Banco Espírito Santo in July. He recently was detained for questioning by Portuguese prosecutors in a money-laundering investigation. He has said he "believes that truth and justice will prevail." A spokesman said Mr. Salgado would speak publicly only when the Bank of Portugal completes its investigation.


The collapse of Portugal's Banco Espírito Santo, whose Lisbon offices are seen above, has sent shock waves through Europe's fragile financial markets. Associated Press Associated Press
The Espírito Santo dynasty started with a foreign-exchange business in Lisbon, launched in 1869 by José María do Espírito Santo e Silva. The business eventually became Banco Espírito Santo and expanded beyond banking into a global empire that included real estate, hotels, health care and energy and agricultural interests. Mr. Salgado, a soft-spoken man with deep blue eyes who is the great-grandson of José Maria, became the bank's CEO in 1991.

In 1999, the family's growing fortune prompted the creation of a separate entity, Eurofin Services, mainly to manage the clan's financing and transactions, according to former Eurofin executives. It was founded by Mr. Cadosch, then a vice president at an Espírito Santo trust company.

Under Mr. Cadosch, Eurofin gradually expanded into offering wealth-management services to other rich families.

By 2008, Eurofin employed about 40. The Espírito Santo family, through a company called Espírito Santo Resources, owned 23% of Eurofin. Its second-largest shareholder, with a 22% stake, was a powerboat-racing promoter named Nicolo di San Germano.

Eurofin tried to diversify. It launched a diamond-trading service. A U.K. unit pitched for investment-banking business with English soccer clubs.

But serving Espírito Santo was always Eurofin's main mission, the internal emails and documents show.

At a May 2008 presentation to Banco Espírito Santo executives, Eurofin officials floated the idea of the bank buying a majority stake in an arm of Eurofin. They noted that the firm's name could be "changed to an Espírito Santo branding," according to a copy of a slideshow. The slides also noted plans, independent of any acquisition, for Eurofin "to develop a range of products" for the bank's clients.

Eurofin managed several investment funds that were sold to clients of Espírito Santo's Swiss private bank, according to Eurofin documents and a former executive. And a stock fund managed by Eurofin counted stakes in Banco Espírito Santo and Espírito Santo Financial Group SA as its two biggest investments, according to marketing documents.

Eurofin was managing more than 1.4 billion Swiss francs ($1.6 billion) of assets for Espírito Santo entities, representing most of Eurofin's total assets under management in 2010, according to an internal Eurofin email.

Not everyone at Espírito Santo was comfortable about the close relationship with Eurofin, the documents show. Before an October 2009 meeting with Espírito Santo, a senior Eurofin executive, Michel Creton, wrote to colleagues to warn them that a top bank executive isn't "friendly" toward Eurofin because of its perceived role serving as a special-purpose financing vehicle. Mr. Creton didn't respond to requests for comment.

That same year, the Espírito Santo family sold its stake in Eurofin, according to Eurofin. The powerboat-racing promoter Mr. di San Germano became Eurofin's majority shareholder.

But the connections between Eurofin and Espírito Santo remained deep, the documents show.

In late 2009, Banco Espírito Santo created a Lisbon trading desk named Tulipa. Its main mission was to sell its customers debt issued by various parts of the Espírito Santo Group, according to a Eurofin memo discussing the project. The memo estimated annual volumes could reach €30 billion, or about $40 billion.

Bank executives turned to Eurofin for help establishing a "paper trail" to "demonstrate the involvement of a third party in the transactions with its clients," according to the Eurofin memo, written after Eurofin executives discussed the setup with bank officials.

Asked about Tulipa, Eurofin said that in 2010 it "set up an intermediary to provide intermediation services as arranger to institutional clients, but these services were never provided to retail clients by Eurofin."

In early 2010, Mr. Creton, the Eurofin executive, flew to Lisbon to meet with Espírito Santo executives. "They were all happy to see that we present ourselves as an independent party with whom they can envisage to work," Mr. Creton emailed his colleagues after the meeting.

Eurofin also helped manage two British Virgin Island-registered investment funds, called EG Premium and Zyrcan. The two funds regularly bought and sold assets and lent money to one another, as well as with Espírito Santo entities, according to internal fund documents. Internal Zyrcan spreadsheets referred to certain counterparties simply as "our friend," which the former executive said was a reference to Espírito Santo.

The former Eurofin executive said the two funds' largest investors were Espírito Santo-owned companies.

In the summer of 2009, Banco Espírito Santo issued so-called zero-coupon bonds with a face value of about €1.8 billion. Zyrcan was the only buyer, and it quickly sold the bonds at prices double or triple what it had paid, according to trading records. A Zyrcan affiliate said in a letter at the time to an intermediary bank that it hoped to profit by selling the bonds in several batches "to clients of Banco Espírito Santo, Lisbon."

On many days from 2009 through 2011, the Zyrcan fund bought tens of millions of dollars of debt issued by Banco Espírito Santo's internal finance arm, providing the bank with a steady stream of liquidity during financial crises, according to trading records.

In the first week of January 2011, for example, Banco Espírito Santo's funding costs were soaring to their highest level in years as anxious investors and banks rushed to curtail their exposure to southern European lenders. That week, Zyrcan bought about €174 million of the bank's long-term bonds, trading records show.

Eurofin said that its Eurofin Capital unit "acts as mere investment advisor" to EG Premium and Zyrcan. Internal fund documents show that senior Eurofin executives, including Mr. Cadosch and the firm's deputy director, Valérie Cholvy, were closely involved with managing the funds and that Eurofin was paid quarterly "management fees." Ms. Cholvy didn't respond to requests for comment.

A large portion of the transactions among Espírito Santo companies, EG Premium and Zyrcan were routed through Caribbean branches of French bank Société Générale SA, GLE.FR -0.28% according to trading records.

In early 2012, employees in Société Générale's compliance department wanted to learn more about the transactions their bank was processing between Eurofin and Espírito Santo entities, according to a person familiar with the matter. Compliance employees repeatedly requested additional information. When they didn't hear back, the French bank stopped serving as an intermediary, this person said.

Things started unraveling late last year.

In November, Portugal's markets regulator imposed a rule limiting the amount that funds could invest in entities affiliated with the fund managers.

The Journal reported in December about Espírito Santo International accounting practices that some outside experts deemed questionable, and noted that Banco Espírito Santo was selling debt issued by other Espírito Santo entities to its retail clients. At the time, Espírito Santo defended its accounting practices and said its sales practices were proper.

That month, the Bank of Portugal told Banco Espírito Santo to reduce its exposure to other Espírito Santo companies, and it requested that KPMG LLP audit Espírito Santo International's books.

This spring, KPMG informed the Bank of Portugal it had uncovered a variety of accounting "irregularities," according the Bank of Portugal's Mr. Costa. In March, the auditor of Espírito Santo International's books, Francisco Machado da Cruz, stepped down from Eurofin's board of directors, according to Eurofin. He didn't respond to requests for comment.

On July 18, Espírito Santo International filed for bankruptcy protection from creditors in Luxembourg.

Banco Espírito Santo's auditors, meanwhile, were finding new areas of exposure to its bankrupt parent. On July 30, the bank reported a €3.6 billion first-half loss, a larger-than-expected blow caused by newly uncovered Espírito Santo debt that had been sold to the bank's retail clients, which the bank said it might have to buy back. The bank said the debt was packaged by financial intermediaries and then sold to clients at an inflated price.

Days later, Mr. Costa identified Eurofin as an intermediary that packaged that debt. Mr. Costa said the securities that Eurofin helped package caused about $1.7 billion in losses for the bank as it set aside money to repay customers.

On Aug. 1, the European Central Bank's governing council, in a lunchtime videoconference, informed the Bank of Portugal that it was cutting off Banco Espírito Santo's access to ECB funds. Two days later, Mr. Costa announced a taxpayer-funded bailout and breakup of the bank.

Eurofin said in its statement that as of June, Espírito Santo "represented a significant part" of its business, although it noted the exposure was "far lower" than a few years ago, when more than two-thirds of its assets were tied to the family.

Mr. di San Germano, the powerboat enthusiast who is majority owner of Eurofin, says he is still trying to figure out what happened. "It was a really big, big surprise to hear" of Eurofin's extensive dealings with Espírito Santo, he said in an interview. "I did not know personally about these things."

Reuters - Yellen resolved to avoid raising rates too soon, f

Yellen resolved to avoid raising rates too soon, fearing downturn

WASHINGTON/NEW YORK (Reuters) - Approaching a historic turn in U.S. monetary policy, Janet Yellen has staked her tenure as chair of the Federal Reserve on a simple principle: she'd rather fight inflation than another economic downturn.

Interviews with current and former Fed officials indicate that Yellen and core decision-makers at the U.S. central bank are determined not to raise interest rates too early and risk hurting the fragile U.S. economy.

It's a commitment that will be vigorously tested in coming months as pressure builds inside the Fed, among Republicans on Capitol Hill, and perhaps even in financial markets, for the Fed to acknowledge a strengthening U.S. economy with its first interest-rate increase in more than eight years. A global central bankers' conference in Jackson Hole, Wyoming next week will give Yellen a major stage on which to press her case.

After taking over from Ben Bernanke in February, she has developed a distinct style: off-the-cuff and personable in public appearances, unusually direct in calling attention to the plight of the unemployed, meticulous in her preparation for Fed meetings and highly attuned to the opinions of her colleagues, the Fed sources say.

A common adjective used to describe her in meetings is "over-prepared." She is able to deeply question staff and colleagues about the fine points of their presentations, and so far has been able to forge consensus statements that have satisfied the Fed hawks most concerned about the inflation threat while keeping the central bank focused more on employment.

The nightmare scenario she wants to avoid is hiking rates only to see financial markets and the economy take such a hit that she has to backtrack. Until the Fed has gotten rates up from the current level near zero to more normal levels, it would have little room to respond if the economy threatened to head into another recession.

Inflation, on the other hand, is a familiar foe that Fed officials say they are confident they can control with conventional policy tools.

"If the Fed were to generate too much economic growth and higher inflation, that is a much better situation to be in than one of a faltering economic recovery and the need to rely even more on unconventional tools," said David Stockton, the Fed's chief economist until 2011 who is now a senior fellow at the Peterson Institute for International Economics.

"The Fed knows how to contain inflation if it is moving," he said, while the impact at this point of another downturn "are more uncertain and hard to counter."

The risks of moving too soon, Stockton and others in and outside the Fed say, include snuffing out an already tepid housing market recovery with higher mortgage rates, depressing business investment and durable goods purchases, and triggering sudden declines in asset prices.

And after extraordinary efforts to right the U.S. economy after the financial crisis struck, there would likely be little appetite among Republicans or other fiscal conservatives on Capitol Hill to use fiscal policy to counter a fresh recession, making it all the more important for Yellen to avoid helping to cause such a reversal.

"The challenge that she and the Fed as an institution face is to support the recovery, because fiscal policy ... is no longer on the table for both political and economic reasons," said David Lipton, first deputy managing director at the International Monetary Fund.  "Now that (the economy) is recovering, the challenge is to gauge its strength and make sure it stays on the right path."

The other scary scenario is that a bout of swifter-than-expected inflation could erode three decades of hard-earned confidence that prices will remain under control, which in turn could make it easier for higher inflation to take firm root. The Fed's more hawkish officials also worry that the longer rates remain ultra low the more likely it is that troublesome financial bubbles will form.

Philadelphia Federal Reserve Bank President Charles Plosser formally dissented over the current dovish approach at the central bank's last policy meeting, while in recent weeks Richard Fisher of the Dallas Fed has amplified his concern that the bank is falling behind the inflation curve.

But even Fisher, one of the Fed's most outspoken hawks, credited Yellen's "extremely thoughtful" way of taking into account the views of other policymakers, a factor he said prompted him not to dissent.   

"She may be new to the chair but she's well respected and she knows all the personalities in the room," said former Fed Governor Elizabeth Duke. Jeffrey Fuhrer, senior policy advisor at the Boston Fed, said Yellen's communications style is "a little more open and accessible" than her predecessor Bernanke. Adding: "She's a bit more approachable somehow."

The central bank is also watching the November mid-term elections with particular interest: a Republican takeover of the Senate could give momentum to a proposal that would force the Fed to rely on a mechanistic rule to set interest rates based on the levels of inflation and unemployment in the economy. That would undermine the collective judgment Yellen feels is needed to guide the economy in the aftermath of the financial crisis.

Despite a falling unemployment rate and inflation that is rising toward the Fed's 2-percent target, Yellen has in the last six months managed to shift investors' attention to stagnant wage growth and the high number of Americans who have given up the search for work.

She recently described higher inflation readings as "noisy," noting that overshooting the target is "at most a risk that we could face somewhere down the road."

At an IMF event in early July, she dropped another strong clue that she was not afraid to let the economy heat up, saying the threat of asset-price bubbles or other financial instabilities probably won't prompt an earlier-than-expected policy tightening.

That speech has been cited by a number of analysts who know Yellen as an important sign that she is putting her stamp on the evolving debate over how deeply central banks should be concerned with financial stability. Yellen was clear: raising rates would almost certainly cost jobs and growth, but wouldn't necessarily stave off bubbles.

In yet another sign of the Fed's patience, San Francisco Fed chief John Williams, often cited as a policy bellwether, recently made the theoretical case for allowing inflation to run temporarily above target to help bring down the number of long-term unemployed. Even broaching the idea of letting inflation run hot is a sensitive topic for a central bank that in the late 1970s and early 80s hiked its key rates to as high as 20 percent to slay sky-rocketing price increases.

Investors currently do not expect the Fed to lift rates until the second half of next year - a remarkable achievement for Yellen given the U.S. unemployment rate is near a six-year low and closing in on what Fed officials see as its equilibrium level.

Colleagues said that Yellen has adapted easily to her new role, yet what Stockton called her "stress test" lies ahead, and may begin this fall when the debate over interest rates intensifies.

The Fed expects to end one of its key crisis programs in October when it stops buying Treasury bonds and mortgage backed securities. Once that happens, the next step is to raise rates.

"You're going to see a battle ... that is wide open" among policymakers, predicted former Fed Vice Chair Alan Blinder.

"There are a zillion ways it could go wrong but the simplest way is that the Fed exits too slowly, in which case some of the fears of the inflation hawks will come true," added Blinder, now a Princeton professor. "The other is that the Fed moves too quickly - this is the one that often gets forgotten - and the recovery stalls or, even worse, gets reversed."

>>> US Close Dow-0,06% S&P-0,16% Nasdaq-0,27%

Closing Market Summary: Stocks and Treasuries Register Modest Losses

The major averages stumbled on Tuesday with the Russell 2000 pacing the slide. The small-cap index lost 0.7%, while the S&P 500 (-0.2%) gave back most of its advance from yesterday. For its part, the Dow Jones Industrial Average (-0.1%) ended with a slim loss.

Equity indices spent the first hour of action near their flat lines after index futures slumped from their overnight highs shortly ahead of the cash open. The early weakness took place as markets in Europe retreated in reaction to disappointing survey data. Specifically, Eurozone ZEW Economic Sentiment plunged to 23.7 from 48.1 (expected 41.3), while Germany's ZEW Economic Sentiment dropped to 8.6 from 27.1 (consensus 18.2).

The news from overseas contributed to the shaky start and so did the underperformance of some closely-watched groups. Most notably, the top-weighted sector—technology (-0.2%)—spent the majority of the trading day in the red amid broad weakness. Chipmakers lagged early, but the PHLX Semiconductor Index was able to narrow its loss to 0.1% by the close. Meanwhile, most large cap tech components underperformed, while Apple (AAPL 95.97, -0.02), IBM (IBM 187.34, -0.13), and Microsoft (MSFT 43.52, +0.32) bucked the trend.

Similar to technology, the energy sector (-0.7%) also kept the market from staging a sustained rebound. The growth-sensitive sector finished near its session low, while crude oil fell 0.7% to $97.35/bbl.

Elsewhere, another influential sector—health care—was able to end just ahead of the broader market even as biotechnology weighed. The iShares Nasdaq Biotechnology ETF (IBB 251.66, -1.55) lost 0.6% and surrendered yesterday's gain.

Like health care, other countercyclical sectors finished near their flat lines. Consumer staples (-0.1%) and utilities (-0.1%) logged modest losses, while the weakest sector of the month—telecom services—added 0.5% to narrow its August decline to 2.5%.

Even though equities endured a sloppy session, participants did not rush in search of volatility protection. In fact, the CBOE Volatility Index (VIX 14.14, -0.09) finished in the red. The modest losses did not translate into higher demand for Treasuries either as the 10-yr note settled on its low with the benchmark yield up two basis points at 2.45%.

Participation was below average with 531 million shares changing hands at the NYSE floor.

Economic data was limited to the Job Opening and Labor Turnover Survey for June and the Treasury Budget for July:

* The Job Openings and Labor Turnover Survey for June indicated job opening increased to 4.671 million from 4.577 million  * The Treasury Budget for July showed a deficit of $94.60 billion, which followed the prior deficit of $97.60 billion, while the Briefing.com consensus expected the deficit to hit $96.00 billion 

Tomorrow, the weekly MBA Mortgage Index will be released at 7:00 ET, while the Retail Sales report for July (consensus 0.3%) will cross the wires at 8:30 ET. Separately, the Business Inventories report for June (consensus 0.4%) will be released at 10:00 ET.

* Nasdaq Composite +5.1% YTD  * S&P 500 +4.6% YTD  * Dow Jones Industrial Average -0.1% YTD  * Russell 2000 -2.6% YTD

WSJ No Satellite of Love for T-Mobile

No Satellite of Love for T-Mobile

For T-Mobile US, it may still take two to tango.
After Sprint's decision last week to shelve a plan to bid for its rival, T-Mobile shareholders who had counted on an offer are scanning for other potential suitors. T-Mobile rejected a request to see its books from French telecom operator Iliad, calling the latter's $15 billion offer for a 56.6% stake too low.
One possible contender: Dish Network. But a deeper look at the satellite company's balance sheet suggests a deal might be hard to swing.
Owning T-Mobile could help Dish put its wireless spectrum holdings to use if the combined company can invest in building a network based on Dish's airwaves. Dish would avoid the regulatory hurdles that quelled Sprint's ambitions.
But Dish and T-Mobile are both issuers of high-yield debt. They would risk their credit ratings if a deal has a big cash component and the combined company has leverage of more than five times trailing earnings before interest, taxes, depreciation and amortization, according to Moody's. And Deutsche Telekom, which owns 67% of T-Mobile, would likely want cash.
Moody's lays out three scenarios, including Dish paying all cash for a 51% stake in T-Mobile, buying Deutsche Telekom's stake for 70% cash and 30% stock, or buying all of T-Mobile for 50% cash and 50% stock. All utilize most of the companies' cash and Moody's also assumes an enterprise value for T-Mobile of $53 billion, or $37 a share plus gross debt, no cost savings and $6 billion to participate in the government's auction for broadcast spectrum. The upshot: the combined company's leverage would reach between 5.6 and 5.8 times Ebitda.
Dish Chairman Charlie Ergen is likely attuned to this dilemma. On a conference call last week, he spoke admiringly of T-Mobile but spent more time extolling the potential of Sprint. T-Mobile investors looking for a deal partner should probably take the hint.

(MergerMarket) European pharma to emerge as consolidators as US targets

European pharma to emerge as consolidators as US targets release key clinical data
• AstraZeneca and GSK could look at InterMune
• Incyte, Pharmacyclics and BioMarin also watched
• Sanofi could eye BioMarin in 2016
European pharmaceutical firms looking to add to their portfolios could take advantage of a slew of US assets releasing late-stage clinical data and a calmer cross-border M&A market due to a possible clampdown on US tax inversion deals, bankers and analysts said.

UK-based AstraZeneca [LON:AZN] and GlaxoSmithKline [LON:GSK], which have spent the first half of the year reorganising their portfolios, could now look to the US in an effort to replenish and enhance existing pipelines, the bankers and analysts said.

Roche [VTX:ROG] and Sanofi [EPA:SAN], which are both on the hunt for acquisitions, could also be sounding out targets across the Atlantic to add advanced technologies and new orphan drug development science, one banker and analyst suggested.

US firms in the USD 5bn-USD 10bn size range would be affordable and provide European bidders with long-term revenues, two bankers and two analysts said. They named InterMune [NASDAQ:ITMN], BioMarin[NASDAQ:BMRN], Incyte Corporation [NASDAQ:INCY] and Pharmacyclics [NASDAQ:PCYC] as targets within this range.

Jazz Pharmaceuticals [NASDAQ:JAZZ] and Salix Pharmaceuticals [NASDAQ:SLXP], which are both UK-headquartered, also fall within this deal range, but European pharma would have to compete with US bidders willing to pay a tax inversion premium, one of the analysts said.

UK giants on the prowl

AstraZeneca and GSK, which have both undertaken strategies that have led them to focus on respiratory disorders, can better reap revenue if they have a presence across the gamut of respiratory indications, the analyst and banker said.

An acquisition of US-based InterMune, which has filed pirfenidone for idiopathic pulmonary fibrosis (IPF) for approval with the US FDA and is awaiting a response in 4Q14, would be a good fit for either AstraZeneca or GSK, they said.

GSK is developing a greater interest in the IPF space, a consulting physician said, while in May this year, AstraZeneca told this news service it was exploring more activity in IPF in its attempts to expand its respiratory portfolio.

GSK declined to comment. AstraZeneca did not return a request for comment.

There are not many firms specifically looking at IPF, so only players with an existing respiratory franchise would pay the price required to do a deal, the banker added. But, the asset would also interest players in inflammatory and orphan diseases, meaning that there would be many firms actively looking at InterMune, a second banker said.

Adding a premium, InterMune could fetch USD 5bn with a potential 10-15% upside if the US FDA approves the drug, pushing the price tag to up to USD 5.5bn - a deal that both GSK and AZ could comfortably afford, the analyst and banker said. With only one product in the late-stage pipeline, one would assume USD 1.5bn-USD 2bn peak sales are needed for InterMune to reach a value of USD 4bn-USD 5bn for a sale, an industry M&A lawyer said.

Bidders have so far refrained from moving in on InterMune, given the regulatory risk associated with pirfenidone's FDA approval quest. But, now that it has been approved in the EU and Canada, buyers are more willing to acquire, the third healthcare banker said.

US regulatory risks have been minimised with recent positive Phase III data presented at the American Thoracic Society (ATS) in May, physicians told this news service. The potential for pirfenidone to be studied in other fibrotic diseases in the lung or other organs are a long way from materialising, the consulting physician said. While GSK and AstraZeneca could find this potential an added bonus, such a possibility would not be compelling enough for non-respiratory focused pharma players, the analyst and banker agreed.

Furthermore, pirfenidone is unlikely to become a blockbuster that justifies its value with only one drug and preclinical candidates years away from success, an IPF physician said. Analyst forecasts of pirfenidone sales have varied from USD 600m to more than USD 1bn.

Intermune’s attraction would be to gain an established IPF sales force and revenue in Europe with the expectation of a US launch in 1H15, the physician said.

Competition from Boehringer Ingelheim’s IPF drug nintedanib, which saw positive Phase III results presented at ATS in May, could also dampen pirfenidone’s market uptake, according to a previousBiopharm Insight report. Boehringer’s existing powerful global respiratory sales force will be hard to compete with, the M&A lawyer added. As both drugs have similar mechanisms of action, uptake will be dependent on marketing execution, said a second consulting physician.

The attractive risk of new science

Roche - which recently snapped up Danish gene silencing company Santaris Pharma for USD 450m - and Sanofi - whose notable acquisition of Genzyme gave it a considerable presence in rare diseases, could both see BioMarin a potential target, one of the bankers and analysts said.

While BioMarin has “interesting science,” any predator would be buying into the company’s future potential, the analyst said. Additionally, Sanofi may be entertaining various options but might not have the appetite for any substantial M&A deals until 2016, the M&A lawyer said.

BioMarin's pipeline readouts are scheduled for June 2015. Its PARP inhibitor (BMN-673) for genetically defined cancers is likely to be an attractive proposition for Roche, the banker suggested. Roche has paid down its Genentech acquisition debt, which will allow it to finance its thirst for technology-driven acquisitions, he added.

Oncology products and companion diagnostics - as would be the case if Roche acquired Pharmacyclics to marry up the Gazyva (obinutuzumab) drug to its diagnostic - remains a core expertise and acquisitive interest for the Swiss giant, one of the bankers said.

Sanofi and Roche could not immediately be reached for comment.

(BFW) Russian Aid to Be Delivered W/In Ukraine Under Red Cross Aegis


BN 08/12 14:21 *RUSSIA IS PUZZLED BY UKRAINE STATEMENT THAT ROUTE NOT AGREED ON
BN 08/12 14:20 *RUSSIAN AID TO BE DELIVERED W/IN UKRAINE UNDER RED CROSS AEGIS
BN 08/12 14:18 *RUSSIA TO DELIVER AID TO BELGOROD-KHARKIV BORDER
BN 08/12 14:16 *RUSSIA COMPLYING W/ UKRAINE WISHES FOR CHECKING AID CARGOES
BFW 08/12 14:16 *RUSSIA IS FOLLOWING UKRAINIAN WISHES ABOUT AID CONVOY ROUTE
BN 08/12 14:16 *RUSSIA IS FOLLOWING UKRAINIAN WISHES ABOUT AID CONVOY ROUTE

Russian Aid to Be Delivered W/In Ukraine Under Red Cross Aegis
2014-08-12 14:26:24.790 GMT


By Torrey Clark
Aug. 12 (Bloomberg) -- Russia to deliver aid to Belgorod-
Kharkiv border.
* NOTE: Earlier, Red Cross Seeking Information on Russian Aid
Convoy to Ukraine {NSN NA75W76TTDS3 <go>}
* NOTE: Earlier, Ukraine to Block Russian Aid Lacking Red
Cross’s Green Light {NSN NA74PV6JIJUS <go>}


For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}

To contact the reporter on this story:
Torrey Clark in Moscow at +7-495-771-7709 or
tclark8@bloomberg.net

To contact the editor responsible for this story:
Joanna Ossinger at +1-212-617-7789 or
jossinger@bloomberg.net

(BFW) TalkTalk to Offer Sky Sports Half Price for Three Months


TalkTalk to Offer Sky Sports Half Price for Three Months
2014-08-12 13:41:54.406 GMT


By Sam Chambers
Aug. 12 (Bloomberg) -- GBP15/month offer begins Aug. 14,
prior to start of Premier League season. Statement
* Aug 7: BT’s bid to offer Sky Sports in time for Premier
League season thwarted by by summer recess: Telegraph


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Sam Chambers in London at +44-20-7673-2021 or
schambers7@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net

(BFW) *ECB SAYS LENDING TO BANKS FELL EU 28.6BLN TO EU 504.9BLN


BFW 08/12 13:00 *ECB SAYS FOREX RESERVES FELL EU100 MLN TO EU213.3 BLN
BFW 08/12 13:00 *ECB SAYS GOLD, GOLD RECEIVABLES REMAINED UNCHANGED IN WEEK

*ECB SAYS LENDING TO BANKS FELL EU 28.6BLN TO EU 504.9BLN
2014-08-12 13:00:08.540 GMT

See {NSN NA72S6BE07IB <GO>} for the Government Web Content - Europe ex UK press release.


-0- Aug/12/2014 13:00 GMT

(BFW) Sanofi Introduces Generic Version of Eloxatin


PRN 08/12 12:50 Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection)
BN 08/12 12:50 *SANOFI LAUNCHES AUTHORIZED GENERIC VERSION OF ELOXATIN®

Sanofi Introduces Generic Version of Eloxatin
2014-08-12 12:55:31.626 GMT


By Allison Connolly
Aug. 12 (Bloomberg) -- Co. says its generics division
Winthrop U.S. has introduced a generic version of Eloxatin
(oxaliplatin injection).
* Sanofi holds original patent; generic is same formulation
* Used in treatment of advanced colorectal cancer or as
adjuvant treatment of stage III colon cancer in patients who
have undergone complete resection of the primary tumor
* NOTE: Branded drug lost market exclusivity in U.S. in Aug.
2012

Link to Statement:{NSN NA72C73MMTC0 <GO>}
Link to Company News:{SAN FP <Equity> CN <GO>}

For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}

To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net

To contact the editor responsible for this story:
Allison Connolly at +44-20-3525-7043 or
aconnolly4@bloomberg.net